Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: costa l. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Consensus on the utility of bone markers in the malignant bone disease setting.
Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, Dimopoulos M, Lipton A. Coleman R, et al. Among authors: costa l. Crit Rev Oncol Hematol. 2011 Dec;80(3):411-32. doi: 10.1016/j.critrevonc.2011.02.005. Epub 2011 Mar 15. Crit Rev Oncol Hematol. 2011. PMID: 21411334 Review.
Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.
Félix J, Andreozzi V, Soares M, Borrego P, Gervásio H, Moreira A, Costa L, Marcelo F, Peralta F, Furtado I, Pina F, Albuquerque C, Santos A, Passos-Coelho JL; Portuguese Group for the Study of Bone Metastases. Félix J, et al. Among authors: costa l. Value Health. 2011 Jun;14(4):499-505. doi: 10.1016/j.jval.2010.11.014. Epub 2011 May 19. Value Health. 2011. PMID: 21669375 Free article.
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Henry D, et al. Among authors: costa l. Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26. Support Care Cancer. 2014. PMID: 24162260 Free article. Clinical Trial.
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials.
Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ. Coleman RE, et al. Among authors: costa l. J Bone Oncol. 2013 Feb 9;2(2):70-6. doi: 10.1016/j.jbo.2013.01.002. eCollection 2013 Jun. J Bone Oncol. 2013. PMID: 26909273 Free PMC article.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B. Aapro M, et al. Among authors: costa l. Ann Oncol. 2008 Mar;19(3):420-32. doi: 10.1093/annonc/mdm442. Epub 2007 Sep 28. Ann Oncol. 2008. PMID: 17906299 Free article. Review.
4,282 results